repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome sars-cov-2
repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome sars-cov-2
the activity of miglustat is here demonstrated for sars-cov-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity.", "the iminosugar miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as gaucher and niemann-pick type c, and has also been described to be active against a variety of enveloped viruses.", "the wealth of available data on the clinical use of miglustat for the treatment of lysosomal storage disorders and the antiviral properties against sars-cov-2 make it an ideal candidate for drug repurposing."


































)